In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression ... week 96 biopsies as treatment failures ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

The board of Sage Therapeutics unanimously rejected ... which for now is to focus on the commercialisation of its post-partum depression (PPD) therapy Zurzuvae (zuranolone). Biogen – which ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

You no doubt are familiar with social determinants of health, items such as food security, housing and transportation, and how inadequacy in those areas can affect well-being. But are you aware of ...

Sage Therapeutics has said it will cut its headcount ... as the first oral therapy for post-partum depression (PPD), but rejected it for major depressive disorder (MDD), a much larger and more ...

Sage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression in August 2023. The drug was commercially ...

Sage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression in August 2023. The drug was commercially ...

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Diversified Energy (OTCQX:DEC) +2.6% pre-market ...